Interestingly, five of the six partial responders in the JVDJ study had high PD-L1–expressing tumours (CPS ≥25%), suggesting that high PD-L1 expression may influence tumour response to combination VEGF inhibition plus PD-1/PD-L1 inhibition in this population. This evidence concerns the gene CD274 and neoplasm.